4.7 Article

Elimination of HDV: Epidemiologic implications and public health perspectives

期刊

LIVER INTERNATIONAL
卷 -, 期 -, 页码 -

出版社

WILEY
DOI: 10.1111/liv.15579

关键词

endemic vs non-endemic countries; HDV prevalence; new HDV therapies; prevention of transmission; risk factors for HDV transmission; screening for HDV; uncertain global epidemiology

向作者/读者索取更多资源

Hepatitis delta virus (HDV) infection is the most severe form of viral hepatitis in humans. It is now recognized as a global public health infection, but accurate prevalence remains uncertain due to lack of good epidemiological studies. Under-screening for HDV is the main reason for underestimating the true burden of infection. Urgent efforts are needed to study HDV using reliable screening tools and surveillance methodologies.
Hepatitis delta virus (HDV) infection causes the severest form of viral hepatitis in humans. Discovered in 1977, it was considered an infection prevalent in the eastern Mediterranean region. Today it is recognized as a global infection of public health importance, however accurate prevalence remains uncertain because of lack of good epidemiological studies. Under-screening for HDV is the single most important factor in under-estimating the true burden of infection. Urgent efforts are therefore needed to apply reliable screening tools and robust surveillance methodologies to study HDV. There is now a move by major hepatology societies to recommend HDV antibody testing in all persons with HBV infection. Important differences also need to be recognized between countries considered endemic or non-endemic countries. While the endemic infections likely spread horizontally in the general population, and is quite often nosocomial, in non-endemic countries special populations may carry the greater burden, such as persons with injection drug use and various sexual exposures. Even in endemic countries, HDV often exists in significant pockets of the general population. HDV has been categorized as an orphan infection due to lack of approved therapies. Recently there have significant advances in therapy and further clinical trials continue. However, as new therapies are approved, equitable access to the medications will become a major public health issue, particularly because most HDV patients live in low or low middle income countries.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据